IOVA Iovance Biotherapeutics Inc
Company Analysis
Latest News
🔴 Iovance Biotherapeutics is trading 4.2% down today as oil prices top $100
Iovance Biotherapeutics is trading 4.2% down now at $8.34 amid broad market weakness, elevated oil prices above $100 and geopolitical tensions. - The Nasdaq...
🟢 Iovance Biotherapeutics is trading 4.03% up today amid biotech sector strength
Iovance Biotherapeutics is trading at $8.61, up 4.03% on September 2, 2026, alongside a 2.75% gain in the XBI biotech ETF amid positive patent news and...
🔴 Iovance Biotherapeutics is trading 4.24% down today
Iovance Biotherapeutics is trading 4.24% down now at $7.67 after no clear company-specific catalyst emerged in the August 31, 2026 search. • August 21...
🔴 Iovance Biotherapeutics is trading 4.32% down today, possibly on profit-taking
Iovance Biotherapeutics is trading 4.32% down at $8.07, with no clear company-specific negative catalyst emerging for August 26, 2026. - Zacks highlighted...
Iovance Biotherapeutics Highlighted as a Top Biotech Stock Pick
On August 26, 2026, Zacks Investment Research featured Iovance Biotherapeutics as one of five biotech stocks recommended for portfolios. The report highlighted...
🟢 Iovance Biotherapeutics is trading 4.44% up today amid 2.06% biotech-sector gains
Iovance Biotherapeutics is trading 4.44% up at $8.42, with biotech-sector momentum the strongest apparent driver as the sector advances 2.06%. - No fresh...
🔴 Iovance Biotherapeutics is trading 4.06% down today after sharp two-session rally
Iovance Biotherapeutics is trading 4.06% down at $8.62 after its sharp two-session rally; no new company-specific announcement explaining the August 21, 2026...
🟢 Iovance Biotherapeutics is trading 11% up today amid broader melanoma-biotech enthusiasm
Iovance Biotherapeutics is trading 10.58% up at $8.84, apparently driven by melanoma-biotech enthusiasm after positive Phase 3 vaccine results from Moderna and...
🟢 Iovance Biotherapeutics is trading 5% up today after positive Phase 3 melanoma-vaccine results
Iovance Biotherapeutics is trading 5% up at $8.39, apparently benefiting from continued biotechnology enthusiasm after Moderna and Merck reported positive...
🟢 Iovance Biotherapeutics is trading 10% up today on positive melanoma-vaccine results from Moderna and Merck
Iovance Biotherapeutics is trading 10% up at $7.74, as biotechnology stocks rally broadly after Moderna and Merck reported positive Phase 3 melanoma-vaccine...
🟢 Iovance Biotherapeutics is trading 9.5% up today as biotech stocks rally on Moderna results
Iovance Biotherapeutics is trading 9.5% up at $7.70, reversing the unexplained 4.6% pre-market decline reported before the August 19, 2026 open, amid a...
🔴 Iovance Biotherapeutics is trading 4.6% down in pre-market amid unexplained trading pressure
Iovance Biotherapeutics is trading 4.6% down at $6.71 in pre-market amid unexplained trading pressure, with no clear company-specific catalyst identified. -...
🟢 Iovance Biotherapeutics is trading 4.52% up today with no clear new catalyst
Iovance Biotherapeutics is trading at $6.82, up +4.52%, with no clear company-specific catalyst identified for August 14, 2026. • No clear company-specific...
🔴 Iovance Biotherapeutics is trading 4.01% down today despite broader U.S. indexes moving higher
Iovance Biotherapeutics is trading 4.01% down at $6.47, despite broader U.S. indexes moving higher on August 13, 2026; no clear company-specific announcement...
Iovance Announces Preliminary Q2 2026 Revenue of ~$99 Million, Beating Guidance
Iovance Biotherapeutics disclosed preliminary second-quarter 2026 financial results and a business update in a new corporate presentation. The company...
Iovance Biotherapeutics' second quarter revenue reached $99M as Amtagvi sales drive 66% growth
Iovance Biotherapeutics reported record financial results for the second quarter 2026, characterized by the accelerating commercial adoption of Amtagvi. The...